By: Robin Lally From: columbia.edu PARP inhibitors have improved survival of breast cancer patients with BRCA1/2 mutations, but the drugs eventually stop working and the cancer returns. A new study of cancer in mice now suggests that a second cancer drug may be able to prevent or delay relapse. “The problem so far has been that the response to PARP …
Fatty acid inhibitor plus chemo could improve treatment efficacy for breast cancer patients with brain metastases
Source: Michigan Medicine – University of Michigan From: news-medical.net A new study from the University of Michigan Health Rogel Cancer Center finds that giving a fatty acid inhibitor alongside chemotherapy could improve the treatment efficacy for patients with brain metastases from triple negative breast cancer. The findings appear in npj Breast Cancer. Previous work has shown that the brain microenvironment …
New tool predicts nerve damage risk from breast cancer treatment
Source: Linköping University Sweden From: news-medical.net Many women treated for breast cancer using taxanes, a type of cytostatic drug, often experience side effects in the nervous system. Researchers at Linköping University in Sweden have developed a tool that can predict the risk level for each individual. The tool could help doctors adapt treatment to avoid persistent side effects in those …
Chemo Hacks: Tips I Used to Make My Breast Cancer Treatment a Bit Easier
By: Deborah Blake-Ontiveros From: webmd.com Going through chemotherapy isn’t exactly a walk in the park. It’s tough, no doubt about it but so are you. I’m currently going through chemo and have picked up some tips and tricks that are making this process a little more bearable. Here are some chemo hacks to help you or your loved one get …
FDA Approves Tepylute for Breast and Ovarian Cancer Treatment
By: Kristi Rosa From: onclive.com The FDA has approved a new drug application for Tepylute, a ready-to-dilute formulation to treat breast and ovarian cancers. The FDA has approved a new drug application (NDA) for Tepylute (formerly SH-105), a ready-to-dilute formulation to treat adenocarcinoma of the breast and ovary.1,2 Tepylute is a liquid form of the standard-of-care agent, thiotepa. The new …
Combination Therapy Shows Promise in Subset of Breast Cancers
By: Olivia Dimmer From: news.feinberg.northwestern.edu Combining two cancer drugs may be a promising treatment for advanced metastatic breast cancer, according to the results of a clinical trial published in the Journal of Clinical Oncology. Breast cancer is the most common cancer in women in the U.S., and roughly one in eight adult women will develop breast cancer in their lifetime, …
New biological mechanism uncovered for treating breast cancer metastasis to the brain
Source: University of Arizona From: news-medical.net A study led by researchers from the University of Arizona Cancer Center at UArizona Health Sciences identified a biological mechanism that could lead to more effective treatments for breast cancer that has metastasized to the brain. By studying the metabolic differences between primary breast cancer cells and those that metastasize to the brain, they determined that …
Tailored Drug Targets Aggressive Breast Cancer
From: insideprecisionmedicine.com Scientists from King’s College London have made a significant breakthrough in the treatment of aggressive breast cancer by developing a tailored drug that exploits the cancer cells’ weaknesses. This innovative approach, published in Clinical Cancer Research and funded by Breast Cancer Now, offers new hope for patients with triple-negative breast cancer, a particularly challenging form of the disease. …
Real-World Study Sheds Light on Treatment Sequences and Second-Line Outcomes in HER2+ Breast Cancer
By: Megan Hollasch From: onclive.com A real-world study published in the International Journal of Clinical Oncology demonstrated that most patients with HER2-positive metastatic breast cancer discontinued second-line treatment in US community practices, which study authors noted underscores the need for timely second-line treatment. Findings from the retrospective cohort revealed that at a median follow-up of 22 months (IQR, 13-37) from …
The Key Role of Primary Care Providers in Managing Breast Cancer Tx-Related AEs
By: Shalmali Pal From: medpagetoday.com Primary care providers play a crucial role in helping manage the side effects of breast cancer treatment. Working alongside oncologists and other specialists, primary care physicians can monitor patients undergoing breast cancer treatment to assess for any adverse events (AEs) or complications and provide symptomatic relief for such common side effects as nausea, fatigue, pain, …